GSK and Innoviva’s Trelegy Ellipta (FF/UMEC/VI) Receive the US FDA’s Approval for Asthma and COPD

 GSK and Innoviva’s Trelegy Ellipta (FF/UMEC/VI) Receive the US FDA’s Approval for Asthma and COPD

GSK and Innoviva’s Trelegy Ellipta (FF/UMEC/VI) Receive the US FDA’s Approval for Asthma and COPD

Shots:

  • The approval is based on an sNDA which includes data from CAPTAIN study assessing Trelegy (qd, 100/62.5/25, 200/62.5/25, 100/31.25/25, and 200/31.25/25 mcg) vs FF/VI (100/25 and 200/25 mcg) to patients whose asthma was inadequately controlled despite treatment with ICS/LABA
  • Results: Trelegy (qd, easy-to-use inhaler) demonstrated improvements in lung function, presented at ERS Congress. The FDA-approved strength for both COPD and asthma is FF/UMEC/VI (100/62.5/25mcg) and additional strength for asthma alone is FF/UMEC/VI (200/62.5/25mcg)
  • Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US

Click here ­to­ read full press release/ article | Ref: GSK | Image: The Indian Express

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post